Apoptotic effect of CKD-602 (Camtobell®) on oral squamous cell carcinoma cell lines

Oral Oncology

Volumn 45, Issue 3, 2009, Pages 266-272

  Ok, Yong Ju ^a   Myoung, Hoon ^a   Kim, Young Kyun ^b   Lee, Jong Ho ^a   Kim, Myung Jin ^a   Yun, Pil Young ^b  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Apoptosis; Camptothecin; CKD 602; Oral squamous cell carcinoma; Topoisomerase I inhibitor

Indexed keywords

BELOTECAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; P53 PROTEIN (325-355), HUMAN; PEPTIDE FRAGMENT;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETICS; METABOLISM; MOUTH MUCOSA; MOUTH NEOPLASMS; SUBMANDIBULAR GLAND NEOPLASMS; TONGUE NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; HUMANS; MOUTH MUCOSA; MOUTH NEOPLASMS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUBMANDIBULAR GLAND NEOPLASMS; TONGUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TOPOISOMERASE I INHIBITORS;

EID: 60249099176     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.05.001     Document Type: Article

References (40)

1. Clayman G.L., Ebihara S., Terada M., Mukai K., and Goepfert H. Report of the tenth international symposium of the foundation for promotion of cancer research: basic and clinical research in head and neck cancer. Jpn J Clin Oncol 27 5 (1997) 361-368
2. Kim K.M., Kim Y.M., Shim Y.S., Kim K.H., Chang H.S., Choi J.O., et al. Epidemiologic survey of head and neck cancers in Korea. J Korean Med Sci 18 1 (2003) 80-87
3. Spiro R.H., Alfonso A.E., Farr H.W., and Strong E.W. Cervical node metastasis from epidermoid carcinoma of the oral cavity and oropharynx. A critical assessment of current staging. Am J Surg 128 4 (1974) 562-567
4. Forastiere A.A., Metch B., Schuller D.E., Ensley J.F., Hutchins L.F., Triozzi P., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol 10 8 (1992) 1245-1251
5. Gottlieb J.A., and Luce J.K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56 1 (1972) 103-105
6. Muggia F.M., Creaven P.J., Hansen H.H., Cohen M.H., and Selawry O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56 4 (1972) 515-521
7. Hsiang Y.H., and Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48 7 (1988) 1722-1726
8. Hsiang Y.H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260 27 (1985) 14873-14878
9. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84 16 (1987) 5565-5569
10. Nitiss J., and Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85 20 (1988) 7501-7505
11. Nieves-Neira W., and Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer 82 3 (1999) 396-404
12. Hertzberg R.P., Caranfa M.J., Holden K.G., Jakas D.R., Gallagher G., Mattern M.R., et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32 3 (1989) 715-720
13. Philippart P., Harper L., Chaboteaux C., Decaestecker C., Bronckart Y., Gordover L., et al. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 6 4 (2000) 1557-1562
14. Lesueur-Ginot L., Demarquay D., Kiss R., Kasprzyk P.G., Dassonneville L., Bailly C., et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 59 12 (1999) 2939-2943
15. Pollack I.F., Erff M., Bom D., Burke T.G., Strode J.T., and Curran D.P. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59 19 (1999) 4898-4905
16. Lee J.H., Lee J.M., Kim J.K., Ahn S.K., Lee S.J., Kim M.Y., et al. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD-602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 21 5 (1998) 581-590
17. Reed J.C., Miyashita T., Takayama S., Wang H.G., Sato T., Krajewski S., et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60 1 (1996) 23-32
18. Chresta C.M., Masters J.R., and Hickman J.A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56 8 (1996) 1834-1841
19. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., et al. Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 9 6 (1994) 1799-1805
20. Koopman G., Reutelingsperger C.P., Kuijten G.A., Keehnen R.M., Pals S.T., and van Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84 5 (1994) 1415-1420
21. Chen C.H., Yang L.M., Lee T.T., Shen Y.C., Zhang D.C., Pan D.J., et al. Antitumor agents - CLI. Bis(helenalinyl)glutarate and bis(isoalantodiol-B)glutarate, potent inhibitors of human DNA topoisomerase II. Bioorg Med Chem 2 2 (1994) 137-145
22. Pommier Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol 23 1 Suppl. 3 (1996) 3-10
23. Husain I., Mohler J.L., Seigler H.F., and Besterman J.M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54 2 (1994) 539-546
24. Kamesaki H. Mechanisms involved in chemotherapy-induced apoptosis and their implications in cancer chemotherapy. Int J Hematol 68 1 (1998) 29-43
25. Sekiguchi I., Suzuki M., Ohwada M., and Sato I. Apoptosis as a criterion for sensitivity of uterine cervical adenocarcinoma to cisplatin. Oncol Rep 5 5 (1998) 1077-1078
26. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 1 (1993) 151-157
27. Jaattela M., Benedict M., Tewari M., Shayman J.A., and Dixit V.M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10 12 (1995) 2297-2305
28. Courtois S.J., Woodworth C.D., Degreef H., and Garmyn M. Early ultraviolet B-induced G1 arrest and suppression of the malignant phenotype by wild-type p53 in human squamous cell carcinoma cells. Exp Cell Res 233 1 (1997) 135-144
29. Yin M.B., Guo B., Vanhoefer U., Azrak R.G., Minderman H., Frank C., et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol 57 3 (2000) 453-459
30. Haldar S., Negrini M., Monne M., Sabbioni S., and Croce C.M. Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 54 8 (1994) 2095-2097
31. Tishler R.B., Calderwood S.K., Coleman C.N., and Price B.D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53 10 Suppl. (1993) 2212-2216
32. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 6 (1993) 957-967
33. Brambilla E., Negoescu A., Gazzeri S., Lantuejoul S., Moro D., Brambilla C., et al. Apoptosis-related factors p53, Bcl-2, and Bax in neuroendocrine lung tumors. Am J Pathol 149 6 (1996) 1941-1952
34. Findley H.W., Gu L., Yeager A.M., and Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89 8 (1997) 2986-2993
35. Li G., Mitchell D.L., Ho V.C., Reed J.C., and Tron V.A. Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. Am J Pathol 148 4 (1996) 1113-1123
36. Tron V.A., Trotter M.J., Tang L., Krajewska M., Reed J.C., Ho V.C., et al. p53-Regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol 153 2 (1998) 579-585
37. Kim K., Lee C.K., Sayers T.J., Muegge K., and Durum S.K. The trophic action of IL-7 on pro-T cells: inhibition of apoptosis of pro-T1, -T2, and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J Immunol 160 12 (1998) 5735-5741
38. Kobayashi T., Ruan S., Clodi K., Kliche K.O., Shiku H., Andreeff M., et al. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 16 12 (1998) 1587-1591
39. Guo B., Yin M.B., Toth K., Cao S., Azrak R.G., and Rustum Y.M. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells. Oncol Res 11 2 (1999) 91-99
40. Uno M., Otsuki T., Yata K., Fujii T., Sakaguchi H., Akisada T., et al. Participation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiation. Int J Oncol 20 3 (2002) 617-622